Navigation Links
BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008
Date:9/4/2008

number of ongoing programs evaluating new forms, applications and

indications of its patent protected RADIESSE dermal filler technology.

The first new commercial product derived from these efforts is expected

to be a form of RADIESSE dermal filler with Lidocaine which may improve

comfort for patients and flow characteristics for physicians, and is

expected to be launched in the United States and Europe in calendar

year 2009.

-- RADIESSE(R) Dermal Filler Post-Market Studies: The Company has

completed and submitted to FDA the results of two post-approval studies

for RADIESSE filler -- a three-year post-approval open-label follow-up

to the pivotal nasolabial fold study to evaluate the long-term safety

and duration of effect with RADIESSE filler, and a study to assess the

safety of RADIESSE dermal filler in nasolabial folds in persons of

color. In the three-year study in nasolabial folds, more than 30% of

treated nasolabial folds were rated by the treating investigator as

improved in patients who were two to three years from their last

injection. No long-term product related adverse events or

delayed-onset adverse events were reported in the study. In the

persons of color study, observed adverse events were typical of dermal

fillers such as redness, swelling, and bruising, and the study found

that RADIESSE dermal filler is safe for use in persons of color. These

studies were conducted pursuant to the requirements of the FDA

associated with the approval for RADIESSE dermal filler for facial

folds and wrinkles.

-- POLIDOCANOL: As announced in a separate press release today, positive

results from the Phase III clinical trial of Polidocanol (European

trade name Aethoxysklerol(R)), a sclerotherapy product for the

treatment of spid
'/>"/>

SOURCE BioForm Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioForm Medical to Present at the 2008 JPMorgan Healthcare Conference on January 7, 2008
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... Forskere kan ansøge ... http://www.openinnovationinscience.at om efteruddannelsesprogrammet "Lab for Open ... Wien .  ... og videnskabsmænd foretaget af Ludwig Boltzmann Gesellschaft ... sundhedsvidenskaben manglen på incitamenter til at undersøge ...
(Date:7/2/2015)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property ... intellectual property, today announced a litigation update. ... Services Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, in ... of Virginia , the Court issued ... key claims in favor of the Defendants on the ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... manufacturing of surgical instruments in Orthopedics, announced today the acquisition of Turner ... world's largest provider of surgical instruments to the Spine Industry. The acquisition of ...
(Date:7/1/2015)... July 1, 2015   Decision Resources Group ... advantages of Otezla are its oral administration, alternative ... reported by surveyed rheumatologists. Otezla was the first ... treatment of active psoriatic arthritis in ... of care includes conventional oral treatments including disease-modifying ...
Breaking Biology Technology:Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3
... Inc. (Nasdaq: CEPH ) today announced positive ... (armodafinil) Tablets [C-IV] in patients experiencing excessive sleepiness associated ... their night shifts (i.e., 4:00 a.m. to 8:00 a.m.), ... significant difference in improvement in overall clinical condition related ...
... 2011 Reportlinker.com announces that a new market research ... Biologic Therapeutic Drugs: Technologies and Global Markets ... market is valued at an estimated $149 billion in ... 2015, a compound annual growth rate (CAGR) of 9.9% ...
... NEW YORK, Jan. 25, 2011 Reportlinker.com ... is available in its catalogue: ... Strategic Implications of Emerging Reimbursement, Technological and ... http://www.reportlinker.com/p0365288/Future-US-In-Vitro-Diagnostics-Market-Strategic-Implications-of-Emerging-Reimbursement-Technological-and-Market-Trends-through-2018.html How ...
Cached Biology Technology:Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder 2Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder 3Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder 4Reportlinker Adds Biologic Therapeutic Drugs: Technologies and Global Markets 2Reportlinker Adds Biologic Therapeutic Drugs: Technologies and Global Markets 3Reportlinker Adds Biologic Therapeutic Drugs: Technologies and Global Markets 4Reportlinker Adds Biologic Therapeutic Drugs: Technologies and Global Markets 5Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 2018 2
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... Department of Materials Science and Engineering at the University ... Materials Science and Technology Division at the Oak Ridge ... of Engineering. He becomes the fifth NAE member in ... the NAE is among the highest professional distinctions accorded ...
... from the University of California, San Diego School of ... broadly regulates how genetic information transcribed from DNA to ... the myriad of proteins necessary for life. The ... , help explain how a relatively limited number of ...
... biomarkers of cardiovascular disease: implications for heart-healthy diets," published ... examined 26 clinical studies and two meta-analyses to assess ... Of the probiotics examined, L. reuteri NCIMB 30242 (Cardioviva) ... dietary requirements by: , Significantly reducing ...
Cached Biology News:University of Tennessee professor named to National Academy of Engineering 2Global regulator of mRNA editing found 2Heart health through gut health 2
... MDS Sciex present the 4000 Q ... hybrid triple quadrupole/linear ion trap mass ... development or proteomics researcher. Innovative Linear ... leaders in mass spectrometry brings together ...
... is an 18 amino acid synthetic peptide whose sequence corresponds to ... peptide is (amino to carboxy terminus): M(1) - A - S ... A - S - P - R - D - A ... peptide may be used for neutralization and control experiments with the ...
... Hollandes is a fixative useful for ... fixation. It is stable and will decalcify ... with Hollande's can be stained successfully with ... the solution stabilizes red blood cell membranes ...
... is a fixative useful for routine procedures. ... is stable and will decalcify small bone ... can be stained successfully with most stains, ... stabilizes red blood cell membranes and cosinophil ...
Biology Products: